Journal Article
. 2021 Mar; 1(12):1153-1166.
doi: 10.1038/s43018-020-00133-0.

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

Isabelle Solomon 1 Maria Amann 2 Anne Goubier 3 Frederick Arce Vargas 1 Dimitrios Zervas 1 Chen Qing 1 Jake Y Henry 1 Ehsan Ghorani 1 Ayse U Akarca 4 Teresa Marafioti 4 Anna Śledzińska 1 Mariana Werner Sunderland 1 Dafne Franz Demane 1 Joanne Ruth Clancy 1 Andrew Georgiou 1 Josephine Salimu 3 Pascal Merchiers 3 Mark Adrian Brown 3 Reto Flury 5 Jan Eckmann 6 Claudio Murgia 5 Johannes Sam 5 Bjoern Jacobsen 7 Estelle Marrer-Berger 7 Christophe Boetsch 7 Sara Belli 7 Lea Leibrock 7 Joerg Benz 7 Hans Koll 6 Roger Sutmuller 5 Karl S Peggs 8 Sergio A Quezada 9 
  • PMID: 33644766
  •     51 References
  •     19 citations


Intratumoral regulatory T cell (Treg) abundance associates with diminished anti-tumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high affinity receptor subunit for IL-2, is a selective target for Treg depletion in mouse and human malignancies; however, anti-human CD25 antibodies have failed to deliver clinical responses against solid tumors due to bystander IL-2 receptor signaling blockade on effector T cells, which limits their anti-tumor activity. Here we demonstrate potent single-agent activity of anti-CD25 antibodies optimized to deplete Tregs whilst preserving IL-2-STAT5 signaling on effector T cells, and demonstrate synergy with immune checkpoint blockade in vivo. Pre-clinical evaluation of an anti-human CD25 (RG6292) antibody with equivalent features demonstrates, in both non-human primates and humanized mouse models, efficient Treg depletion with no overt immune-related toxicities. Our data supports the clinical development of RG6292 and evaluation of novel combination therapies incorporating non-IL-2 blocking anti-CD25 antibodies in clinical studies.

Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.
Emma Jones, Michaela Dahm-Vicker, +4 authors, Awen Gallimore.
Cancer Immun, 2003 May 16; 2. PMID: 12747746
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
S Onizuka, I Tawara, +3 authors, E Nakayama.
Cancer Res, 1999 Jul 09; 59(13). PMID: 10397255
Highly Cited.
Basiliximab, mechanism of action and pharmacological properties.
Elvedina Kapic, Fahir Becic, Jasna Kusturica.
Med Arh, 2005 Jan 15; 58(6). PMID: 15648237
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
Jose M González-Navajas, Dengxia Denise Fan, +4 authors, Jongdae Lee.
Front Immunol, 2021 Mar 16; 12. PMID: 33717139    Free PMC article.
Hyperprogressive Disease: Main Features and Key Controversies.
Hugo Arasanz, Miren Zuazo, +15 authors, Ruth Vera.
Int J Mol Sci, 2021 May 01; 22(7). PMID: 33916696    Free PMC article.
Glycosylation of Immune Receptors in Cancer.
Ruoxuan Sun, Alyssa Min Jung Kim, Seung-Oe Lim.
Cells, 2021 Jun 03; 10(5). PMID: 34064396    Free PMC article.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
Paolo A Ascierto, Christian Blank, +20 authors, Magdalena Thurin.
J Transl Med, 2021 Jul 02; 19(1). PMID: 34193182    Free PMC article.
Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
Shirley Tenesaca, Marcos Vasquez, +10 authors, Pedro Berraondo.
J Immunother Cancer, 2021 Jul 30; 9(7). PMID: 34321273    Free PMC article.
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Hiroyoshi Nishikawa, Shohei Koyama.
J Immunother Cancer, 2021 Aug 01; 9(7). PMID: 34330764    Free PMC article.
Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.
Aikaterini Hatzioannou, Athina Boumpas, +4 authors, Panayotis Verginis.
Front Immunol, 2021 Sep 21; 12. PMID: 34539668    Free PMC article.
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.
Julia Dahlhoff, Hannah Manz, +13 authors, Andreas Beilhack.
Leukemia, 2021 Sep 30; 36(3). PMID: 34584204    Free PMC article.
Antibody-guided design and identification of CD25-binding small antibody mimetics using mammalian cell surface display.
Kyra See, Tetsuya Kadonosono, +9 authors, Shinae Kizaka-Kondoh.
Sci Rep, 2021 Nov 13; 11(1). PMID: 34764369    Free PMC article.
Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells.
Yifan Xie, Feng Xie, +7 authors, Fangfang Zhou.
Adv Sci (Weinh), 2021 Oct 19; 8(22). PMID: 34658167    Free PMC article.
Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Jessica Waibl Polania, Emily C Lerner, +2 authors, Peter E Fecci.
Front Immunol, 2021 Dec 07; 12. PMID: 34868044    Free PMC article.
The Blockade of Interleukin-2 During the Acute Phase of Trypanosoma cruzi Infection Reveals Its Dominant Regulatory Role.
Jorge Nihei, Fabiola Cardillo, Jose Mengel.
Front Cell Infect Microbiol, 2021 Dec 07; 11. PMID: 34869064    Free PMC article.
Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.
Devayani Machiraju, Sarah Schäfer, Jessica C Hassel.
Life (Basel), 2021 Dec 25; 11(12). PMID: 34947849    Free PMC article.
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Monika Semmrich, Jean-Baptiste Marchand, +15 authors, Björn Frendéus.
J Immunother Cancer, 2022 Jan 22; 10(1). PMID: 35058324    Free PMC article.
Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
Shingo Maeda, Tomoki Motegi, +8 authors, Yasuyuki Momoi.
J Immunother Cancer, 2022 Feb 09; 10(2). PMID: 35131860    Free PMC article.
Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies.
Kevin Park, Mysore S Veena, Daniel Sanghoon Shin.
Front Cell Dev Biol, 2022 Mar 30; 10. PMID: 35345849    Free PMC article.
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Alexey Revenko, Larissa S Carnevalli, +25 authors, A Robert MacLeod.
J Immunother Cancer, 2022 Apr 08; 10(4). PMID: 35387780    Free PMC article.
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Yan Tie, Fan Tang, Yu-Quan Wei, Xia-Wei Wei.
J Hematol Oncol, 2022 May 19; 15(1). PMID: 35585567    Free PMC article.
Novel Immunotherapies for Osteosarcoma.
Yubao Lu, Jiahe Zhang, +4 authors, Cangyu Zhang.
Front Oncol, 2022 Apr 19; 12. PMID: 35433427    Free PMC article.